Literature DB >> 32451710

A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reaction.

Zhao Cheng1, Yunya Luo1, Yang Zhang2, Yewei Wang1, Yi Chen1, Yunxiao Xu1, Honling Peng1, Guangsen Zhang3.   

Abstract

NUT midline carcinoma (NMC) is an aggressive neoplasm and mainly involved in the head and neck area. The defining genetic hallmark on these tumors is that testis-specific nuclear gene (NUTM1) fuses to bromodomain protein family member 4 gene (BRD4), resulting in the formation of BRD4-NUTM1 transcript. Here, we report a case with myeloid neoplasm complicating with eosinophilia (MLN-Eo) and rearrangement of PDGFRA, which co-exists with a new nucleosome assemble protein 1-like 4 gene (NAP1L4) NAP1L4-NUTM1 fusion. The patient have unusually clinical features and therapeutic reaction to imatinib mesylate. The cloned NAP1L4-NUTM1 gene structure is also determined.

Entities:  

Keywords:  Eosinophilia; Myeloid neoplasm; NAP1L4/NUTM1 fusion

Year:  2020        PMID: 32451710     DOI: 10.1007/s00277-020-04000-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  3 in total

1.  Case report: NUT carcinoma in an elderly woman with unique morphology and immunophenotype highlights a diagnostic pitfall.

Authors:  Xuejing Wei; Xiaojing Teng; Yanning Zhang; Ming Cheng; Guangyong Chen
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

Review 2.  Interplay between cofactors and transcription factors in hematopoiesis and hematological malignancies.

Authors:  Zi Wang; Pan Wang; Yanan Li; Hongling Peng; Yu Zhu; Narla Mohandas; Jing Liu
Journal:  Signal Transduct Target Ther       Date:  2021-01-20

Review 3.  NUTM1-Rearranged Neoplasms-A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations-An Updated Review.

Authors:  Wenyi Luo; Todd M Stevens; Phillip Stafford; Markku Miettinen; Zoran Gatalica; Semir Vranic
Journal:  Curr Oncol       Date:  2021-11-07       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.